BioSpace News Archive

CytoSorbents Corporation announced that the Company has been granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the U.S. Food and Drug Administration (FDA).

Exicure, Inc. today reported financial results for the quarter ended June 30, 2021 and provided an update on corporate progress.

Cybin Inc. is pleased to announce that Adelia Therapeutics Inc. (“ Adelia ”), a wholly-controlled subsidiary of Cybin, has achieved certain milestones for Year 1 Q3 (i)-(iii), and Year 1 Q4 (iii), as contemplated by the terms of a contribution agreement dated December 4, 2020

Schrödinger, Inc. today announced financial results for the quarter ended June 30, 2021, and provided an update on the company.

Medexus Pharmaceuticals Inc. today announced that is has completed enrollment in its Phase 4 Clinical Trial of IXINITY ® , targeting label expansion for pediatric hemophilia B patients.

Microbix Biosystems Inc. reports results for its third quarter and nine months of fiscal 2021 ending June 30, 2021 (“ Q3 ” and “ YTD ”), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from innovative, proprietary, and branded medical devices.

Monte Rosa Therapeutics, Inc. today reported business highlights and financial results for the second quarter, ended June 30, 2021.

VYNE Therapeutics Inc. today announced financial results for the second quarter ended June 30, 2021.

Nuvo Pharmaceuticals Inc. today announced Health Canada has issued a Notice of Compliance (NOC) in relation to the Company’s Supplement to New Drug Submission for the pediatric use of Blexten.

Aerie Pharmaceuticals, Inc. today announced that Casey C. Kopczynski, Ph.D., Chief Scientific Officer, will participate in a virtual panel discussion on Tuesday, August 17, 2021 at 9:00 a.m. Eastern Time.